High-yield soluble expression of recombinant influenza virus antigens from Escherichia coli and their potential uses in diagnosis

Journal of Virological Methods

Volumn 196, Issue , 2014, Pages 56-64

  Jang, Yo Han ^a   Cho, Seung Hee ^a   Son, Ahyun ^a   Lee, Yun Ha ^a   Lee, Jinhee ^a   Lee, Kwang Hee ^a   Seong, Baik Lin ^a  

^a Yonsei University   (South Korea)

Author keywords

Antibody library; Bacteria; ELISA; Fusion partner; Influenza viruses; Recombinant proteins

Indexed keywords

HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; LYSINE TRANSFER RNA LIGASE; LYSRS HA PROTEIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIBODY LIBRARY; BACTERIA; ELISA; FUSION PARTNER; INFLUENZA VIRUSES; RECOMBINANT PROTEINS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MICE; MICE, INBRED BALB C; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 84888123350     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.10.035     Document Type: Article

References (40)

1. Aguilar-Yanez J.M., Portillo-Lara R., Mendoza-Ochoa G.I., Garcia-Echauri S.A., Lopez-Pacheco F., Bulnes-Abundis D., Salgado-Gallegos J., Lara-Mayorga I.M., Webb-Vargas Y., Leon-Angel F.O., Rivero-Aranda R.E., Oropeza-Almazan Y., Ruiz-Palacios G.M., Zertuche-Guerra M.I., DuBois R.M., White S.W., Schultz-Cherry S., Russell C.J., Alvarez M.M. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS ONE 2010, 5:e11694.
2. Baneyx F. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 1999, 10:411-421.
3. Bosch B.J., Bodewes R., de Vries R.P., Kreijtz J.H., Bartelink W., van Amerongen G., Rimmelzwaan G.F., de Haan C.A., Osterhaus A.D., Rottier P.J. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 2010, 84:10366-10374.
4. Choi S.I., Han K.S., Kim C.W., Ryu K.S., Kim B.H., Kim K.H., Kim S.I., Kang T.H., Shin H.C., Lim K.H., Kim H.K., Hyun J.M., Seong B.L. Protein solubility and folding enhancement by interaction with RNA. PLoS ONE 2008, 3:e2677.
5. Choi S.I., Lim K.H., Seong B.L. Chaperoning roles of macromolecules interacting with proteins in vivo. Int. J. Mol. Sci. 2011, 12:1979-1990.
6. Choi S.I., Ryu K., Seong B.L. RNA-mediated chaperone type for de novo protein folding. RNA Biol. 2009, 6:21-24.
7. Choi S.I., Son A., Lim K.H., Jeong H., Seong B.L. Macromolecule-assisted de novo protein folding. Int. J. Mol. Sci. 2012, 13:10368-10386.
8. Davis A.R., Nayak D.P., Ueda M., Hiti A.L., Dowbenko D., Kleid D.G. Expression of antigenic determinants of the hemagglutinin gene of a human influenza virus in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:5376-5380.
9. Davis G.D., Elisee C., Newham D.M., Harrison R.G. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng. 1999, 65:328-382.
10. DuBois R.M., Aguilar-Yanez J.M., Mendoza-Ochoa G.I., Oropeza-Almazan Y., Schultz-Cherry S., Alvarez M.M., White S.W., Russell C.J. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J. Virol. 2011, 85:865-872.
11. Ebrahimi S.M., Tebianian M., Aghaiypour K., Nili H., Mirjalili A. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. Mol. Biol. Rep. 2010, 37:2909-2914.
12. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., Adler-Moore J.P., Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
13. Esposito D., Chatterjee D.K. Enhancement of soluble protein expression through the use of fusion tags. Curr. Opin. Biotechnol. 2006, 17:353-358.
14. Feng J., Gulati U., Zhang X., Keitel W.A., Thompson D.M., James J.A., Thompson L.F., Air G.M. Antibody quantity versus quality after influenza vaccination. Vaccine 2009, 27:6358-6362.
15. Fouchier R.A., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., Osterhaus A.D. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 2005, 79:2814-2822.
16. Fox J.D., Waugh D.S. Maltose-binding protein as a solubility enhancer. Methods Mol. Biol. 2003, 205:99-117.
17. Frankel A.D., Smith C.A. Induced folding in RNA-protein recognition: more than a simple molecular handshake. Cell 1998, 92:149-151.
18. Huang B., Wang W., Li R., Wang X., Jiang T., Qi X., Gao Y., Tan W., Ruan L. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol. J. 2012, 9:322.
19. Jang Y.H., Byun Y.H., Lee K.H., Park E.S., Lee Y.H., Lee Y.J., Lee J., Kim K.H., Seong B.L. Host defense mechanism-based rational design of live vaccine. PLoS ONE 2013, 8:e75043.
20. Jones I.M., Brownlee G.G. Differential expression of influenza N protein and neuraminidase antigenic determinants in Escherichia coli. Gene 1985, 35:333-342.
21. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., King L.R., Ross T.M., Golding H. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010, 5:e11548.
22. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., King L.R., Ross T.M., Golding H. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 2011, 85:1246-1256.
23. Kilbourne E.D., Cerini C.P., Khan M.W., Mitchell J.W., Ogra P.L. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. 1987, 138:3010-3013.
24. Kim C.W., Han K.S., Ryu K.S., Kim B.H., Kim K.H., Choi S.I., Seong B.L. N-terminal domains of native multidomain proteins have the potential to assist de novo folding of their downstream domains in vivo by acting as solubility enhancers. Protein Sci. 2007, 16:635-643.
25. Krug R.A.L.R.M. Orthomyxoviridae: the viruses and their replication. Fields Virology 2001, 1487-1532. Lippincott Williams & Wilkins, Philadelphia. M. David, P.M.H. Knipe (Eds.).
26. Murugan S., Ponsekaran S., Kannivel L., Mangamoori L.N., Chandran D., Villuppanoor Alwar S., Chakravarty C., Lal S.K. Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice. J. Virol. Methods 2013, 187:20-25.
27. Nallamsetty S., Waugh D.S. Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. Protein Exp. Purif. 2006, 45:175-182.
28. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
29. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
30. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
31. Potter C.W. A history of influenza. J. Appl. Microbiol. 2001, 91:572-579.
32. Rentzeperis D., Jonsson T., Sauer R.T. Acceleration of the refolding of Arc repressor by nucleic acids and other polyanions. Nat. Struct. Biol. 1999, 6:569-573.
33. Seo S.U., Byun Y.H., Lee E.Y., Jung E.J., Jang Y.H., Kim H.A., Ha S.H., Lee K.H., Seong B.L. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine 2008, 26:874-881.
34. Smith D.B., Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988, 67:31-40.
35. Treanor J.J., Betts R.F., Smith G.E., Anderson E.L., Hackett C.S., Wilkinson B.E., Belshe R.B., Powers D.C. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 1996, 173:1467-1470.
36. Uversky V.N., Gillespie J.R., Fink A.L. Why are natively unfolded proteins unstructured under physiologic conditions?. Proteins 2000, 41:415-427.
37. Uyeki T.M., Cox N.J. Global concerns regarding novel influenza A (H7N9) virus infections. New Engl. J. Med. 2013, 368:1862-1864.
38. Vijaykrishna D., Bahl J., Riley S., Duan L., Zhang J.X., Chen H., Peiris J.S., Smith G.J., Guan Y. Evolutionary dynamics and emergence of panzootic H5N1 influenza viruses. PLoS Pathog. 2008, 4:e1000161.
39. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., Yang Z.Y., Dell A., Haslam S.M., Wilson I.A., Nabel G.J. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 2008, 82:6200-6208.
40. Young C.L., Britton Z.T., Robinson A.S. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnol. J. 2012, 7:620-634.